Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 2Endocrine 2Sarcoma 1Lymphoid 1Gastrointestinal 1Breast 1

Conditions

Sarcoma 9Breast Neoplasms 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Sarcoma, Ewing 2Salivary Gland Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Gliosarcoma 2Glioblastoma 2Cholangiocarcinoma 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Tongue Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Solitary Fibrous Tumors 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Rectal Neoplasms 1Prostatic Neoplasms 1Pheochromocytoma 1Penile Neoplasms 1Paraganglioma 1

Interventions

tivozanib 1repotrectinib 1pembrolizumab 1dostarlimab 1atezolizumab 1Fluorodeoxyglucose F18 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Neuroendocrine × Fluorodeoxyglucose F18 × Sarcoma × Clear all
NCT05396118 2024-05-14

Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients

Rigshospitalet, Denmark

Phase 2 Unknown
15 enrolled
BreastEndocrineLymphoidNETSarcoma

Breast Neoplasms, Lymphoma, Sarcoma, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡